UBI Pharma Inc. reported earnings results for the half year ended June 30, 2022. For the half year, the company reported sales was TWD 319.02 million compared to TWD 277.33 million a year ago. Net income was TWD 19.34 million compared to net loss of TWD 39.22 million a year ago.

Basic earnings per share from continuing operations was TWD 0.18 compared to basic loss per share from continuing operations of TWD 0.43 a year ago. Diluted earnings per share from continuing operations was TWD 0.18 compared to diluted loss per share from continuing operations of TWD 0.43 a year ago.